{"id":{"repo_id":"birmingham","oai_identifier":"oai:etheses.bham.ac.uk:3622"},"canonical_url":"https://search.ndltd.org/etd/birmingham/oai:etheses.bham.ac.uk:3622","repository":{"repo_id":"birmingham","name":"University of Birmingham","base_url":"https://etheses.bham.ac.uk/cgi/oai2"},"display":{"title":"Engineering an improved dendritic cell vaccine expressing whole antigen following non-viral transfection","abstract":"Dendritic cells are efficient antigen-presenting-cells that can be used in tumour-antigen specific vaccination for malignant disease. Melanoma patients were recently treated with a dendritic cell vaccine expressing gp100 and Melan-A antigens after non-viral (CL22 peptide) transfection. Although clinical and immunological responses were noted, there was no correlation between responses and whole antigen expression levels in the vaccine cells that varied widely. Here, it is established that patient cells expressed detectable levels of Class I restricted epitopes from both antigens, although there was no correlation with whole antigen detection. CL22 transfected dendritic cells could simultaneously present a viral antigen (EBNA1) to CD8 and CD4 T-cells, which had not previously been demonstrated. Using RNA transfection, it was demonstrated that early after transfection cells are whole Melan-A positive yet negative for Class I epitopes and with time Melan-A antigen levels fall whilst Class I epitopes are generated. Loss of whole antigen expression seemed related to lysosomal function and, unlike the viral antigen EBNA1, Class I presentation from Melan-A was lysosome-dependent. For Class II presentation of EBNA1, cellular localisation seems to determine access to the Class II pathway although this depends on the time-scale over which epitope presentation is assessed.","abstract_html":"Dendritic cells are efficient antigen-presenting-cells that can be used in tumour-antigen specific vaccination for malignant disease. Melanoma patients were recently treated with a dendritic cell vaccine expressing gp100 and Melan-A antigens after non-viral (CL22 peptide) transfection. Although clinical and immunological responses were noted, there was no correlation between responses and whole antigen expression levels in the vaccine cells that varied widely. Here, it is established that patient cells expressed detectable levels of Class I restricted epitopes from both antigens, although there was no correlation with whole antigen detection. CL22 transfected dendritic cells could simultaneously present a viral antigen (EBNA1) to CD8 and CD4 T-cells, which had not previously been demonstrated. Using RNA transfection, it was demonstrated that early after transfection cells are whole Melan-A positive yet negative for Class I epitopes and with time Melan-A antigen levels fall whilst Class I epitopes are generated. Loss of whole antigen expression seemed related to lysosomal function and, unlike the viral antigen EBNA1, Class I presentation from Melan-A was lysosome-dependent. For Class II presentation of EBNA1, cellular localisation seems to determine access to the Class II pathway although this depends on the time-scale over which epitope presentation is assessed.","abstract_has_math":false,"creators":["Rao, Ankit Rohit"],"institution":"University of Birmingham","degree_name":"d_ph","degree_level":"d_ph","degree_discipline":null,"degree_department":null,"school":null,"contributors":[],"advisors":[],"committee_chairs":[],"committee_members":[],"year":2012,"date_issued":"2012-12","date_published":"2012-12","updated_at":"2026-11-19T09:27:16Z","subjects":["QR180 Immunology","QR355 Virology","RC0254 Neoplasms. Tumors. Oncology (including Cancer)"],"languages":["eng"],"rights":[],"rights_urls":[],"identifier_entries":[],"person_identifier_entries":[]},"links":{"outbound_url":null,"outbound_label":null,"outbound_source":null,"record_url":null,"record_label":null,"record_kind":null,"record_source":null,"download_url":"http://etheses.bham.ac.uk//id/eprint/3622/1/Rao12PhD.pdf","download_label":"Download PDF","download_source":"dc:identifier.uri","access_status":null,"embargo_until":null,"access_note":null},"source_record":{"url":"https://etheses.bham.ac.uk/cgi/oai2?verb=GetRecord&metadataPrefix=uketd_dc&identifier=oai%3Aetheses.bham.ac.uk%3A3622","prefix":"uketd_dc"},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:contributor.sponsor","label":"Sponsor","values":["na"]},{"key":"dc:creator","label":"Author","values":["Rao, Ankit Rohit"]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"dc:date","label":"Dc Date","values":["2012-12"]},{"key":"dc:date.issued","label":"Date","values":["2012-12"]},{"key":"dc:publisher.department","label":"Dc Publisher Department","values":["College of Medical & Dental Sciences","Institute of Cancer Studies"]},{"key":"dc:publisher.institution","label":"Dc Publisher Institution","values":["University of Birmingham"]},{"key":"dc:relation.isreferencedby","label":"Dc Relation Isreferencedby","values":["http://etheses.bham.ac.uk//id/eprint/3622/"]},{"key":"dc:type","label":"Dc Type","values":["Thesis"]},{"key":"dc:type.qualificationlevel","label":"Dc Type Qualificationlevel","values":["d_ph"]},{"key":"dc:type.qualificationname","label":"Dc Type Qualificationname","values":["d_ph"]}]},{"id":"subjects_keywords","label":"Subjects and Keywords","entries":[{"key":"dc:subject","label":"Dc Subject","values":["QR180 Immunology","QR355 Virology","RC0254 Neoplasms. Tumors. Oncology (including Cancer)"]}]},{"id":"language_rights","label":"Language and Rights","entries":[{"key":"dc:language.dcterms_iso639_2","label":"Language (ISO 639-2)","values":["eng"]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier.uri","label":"Identifier URI","values":["http://etheses.bham.ac.uk//id/eprint/3622/1/Rao12PhD.pdf","http://etheses.bham.ac.uk//id/eprint/3622/2/Decl_IS_Rao12PhD.pdf"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:description.abstract","label":"Abstract","values":["Dendritic cells are efficient antigen-presenting-cells that can be used in tumour-antigen specific vaccination for malignant disease. Melanoma patients were recently treated with a dendritic cell vaccine expressing gp100 and Melan-A antigens after non-viral (CL22 peptide) transfection. Although clinical and immunological responses were noted, there was no correlation between responses and whole antigen expression levels in the vaccine cells that varied widely. Here, it is established that patient cells expressed detectable levels of Class I restricted epitopes from both antigens, although there was no correlation with whole antigen detection. CL22 transfected dendritic cells could simultaneously present a viral antigen (EBNA1) to CD8 and CD4 T-cells, which had not previously been demonstrated. Using RNA transfection, it was demonstrated that early after transfection cells are whole Melan-A positive yet negative for Class I epitopes and with time Melan-A antigen levels fall whilst Class I epitopes are generated. Loss of whole antigen expression seemed related to lysosomal function and, unlike the viral antigen EBNA1, Class I presentation from Melan-A was lysosome-dependent. For Class II presentation of EBNA1, cellular localisation seems to determine access to the Class II pathway although this depends on the time-scale over which epitope presentation is assessed."]},{"key":"dc:format","label":"Dc Format","values":["application/pdf"]},{"key":"dcterms:accessrights","label":"Dcterms Accessrights","values":["public","staffonly"]},{"key":"dc:title","label":"Title","values":["Engineering an improved dendritic cell vaccine expressing whole antigen following non-viral transfection"]}]}],"canonical_facts":{"dc:contributor.sponsor":["na"],"dc:creator":["Rao, Ankit Rohit"],"dc:date":["2012-12"],"dc:date.issued":["2012-12"],"dc:description.abstract":["Dendritic cells are efficient antigen-presenting-cells that can be used in tumour-antigen specific vaccination for malignant disease. Melanoma patients were recently treated with a dendritic cell vaccine expressing gp100 and Melan-A antigens after non-viral (CL22 peptide) transfection. Although clinical and immunological responses were noted, there was no correlation between responses and whole antigen expression levels in the vaccine cells that varied widely. Here, it is established that patient cells expressed detectable levels of Class I restricted epitopes from both antigens, although there was no correlation with whole antigen detection. CL22 transfected dendritic cells could simultaneously present a viral antigen (EBNA1) to CD8 and CD4 T-cells, which had not previously been demonstrated. Using RNA transfection, it was demonstrated that early after transfection cells are whole Melan-A positive yet negative for Class I epitopes and with time Melan-A antigen levels fall whilst Class I epitopes are generated. Loss of whole antigen expression seemed related to lysosomal function and, unlike the viral antigen EBNA1, Class I presentation from Melan-A was lysosome-dependent. For Class II presentation of EBNA1, cellular localisation seems to determine access to the Class II pathway although this depends on the time-scale over which epitope presentation is assessed."],"dc:format":["application/pdf"],"dc:identifier.uri":["http://etheses.bham.ac.uk//id/eprint/3622/1/Rao12PhD.pdf","http://etheses.bham.ac.uk//id/eprint/3622/2/Decl_IS_Rao12PhD.pdf"],"dc:language.dcterms_iso639_2":["eng"],"dc:publisher.department":["College of Medical & Dental Sciences","Institute of Cancer Studies"],"dc:publisher.institution":["University of Birmingham"],"dc:relation.isreferencedby":["http://etheses.bham.ac.uk//id/eprint/3622/"],"dc:subject":["QR180 Immunology","QR355 Virology","RC0254 Neoplasms. Tumors. Oncology (including Cancer)"],"dcterms:accessrights":["public","staffonly"],"dc:title":["Engineering an improved dendritic cell vaccine expressing whole antigen following non-viral transfection"],"dc:type":["Thesis"],"dc:type.qualificationlevel":["d_ph"],"dc:type.qualificationname":["d_ph"]},"updated_at":"2026-11-19T09:27:16Z"}